)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Pharmesis International
Pharmesis International (BFK) investor relations material
Pharmesis International H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary14 Aug, 2026
Executive summary
H1 2026 revenue fell 56.4% YoY to RMB11.9m amid weaker product sales, market competition and pricing pressure; net loss widened to RMB4.4m from RMB1.4m.
Operating cash flow turned positive at RMB1.3m, and cash rose to RMB5.3m at 30 June 2026 from RMB4.3m at year-end 2025.
Financial highlights
Revenue was RMB11.865m, down 56.4% YoY; gross profit fell 61.0% to RMB4.028m.
Gross margin declined to 34.0% from 38.0% in H1 2025, mainly due to lower margin on ATT products.
Operating loss widened to RMB4.065m from RMB1.039m; net loss was RMB4.360m versus RMB1.372m.
Other income rose to RMB1.167m from RMB0.670m, mainly on higher rental income and government grants; selling and distribution costs fell to RMB2.963m.
Basic and diluted loss per share was RMB13.8 cents, versus RMB4.3 cents in H1 2025.
Outlook and guidance
Management expects a challenging year ahead and plans a cautious operating approach, prioritizing sales growth and stringent cost management.
The focus remains on revenue growth, margin improvement and prudent capital expenditure to support sustainable cash generation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Pharmesis International
- Flood disruption and falling sales deepened FY2023 losses as liquidity tightened.BFK
H2 2023 - Lower TCM demand and ATT cost inflation widened the H1 loss; outlook remains challenging.BFKH1 2024
- TCH procurement drove revenue growth and a return to FY2024 profitability, despite lower gross margins.BFKH2 2024
- Revenue growth and margin gains narrowed losses, but liquidity remained tight.BFKH1 2025
- Core drug sales grew, but the loss of TCH procurement revenue drove a FY2025 net loss.BFKH2 2025
Next Pharmesis International earnings date
H2 202626 Feb, 2027
Pharmesis International
Next Pharmesis International earnings date
H2 202626 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)